PL2721039T3 - Chelatowane inhibitory PSMA - Google Patents
Chelatowane inhibitory PSMAInfo
- Publication number
- PL2721039T3 PL2721039T3 PL12731239T PL12731239T PL2721039T3 PL 2721039 T3 PL2721039 T3 PL 2721039T3 PL 12731239 T PL12731239 T PL 12731239T PL 12731239 T PL12731239 T PL 12731239T PL 2721039 T3 PL2721039 T3 PL 2721039T3
- Authority
- PL
- Poland
- Prior art keywords
- psma inhibitors
- chelated
- chelated psma
- inhibitors
- psma
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161497206P | 2011-06-15 | 2011-06-15 | |
| US201261647932P | 2012-05-16 | 2012-05-16 | |
| EP12731239.5A EP2721039B1 (en) | 2011-06-15 | 2012-06-13 | Chelated psma inhibitors |
| PCT/US2012/042283 WO2012174136A1 (en) | 2011-06-15 | 2012-06-13 | Chelated psma inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2721039T3 true PL2721039T3 (pl) | 2018-06-29 |
Family
ID=46420539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12731239T PL2721039T3 (pl) | 2011-06-15 | 2012-06-13 | Chelatowane inhibitory PSMA |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9446157B2 (pl) |
| EP (1) | EP2721039B1 (pl) |
| CN (2) | CN103930432B (pl) |
| CA (1) | CA2839195C (pl) |
| ES (1) | ES2657863T3 (pl) |
| PL (1) | PL2721039T3 (pl) |
| WO (1) | WO2012174136A1 (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10717750B2 (en) * | 2009-03-19 | 2020-07-21 | The Johns Hopkins University | 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| WO2012064914A2 (en) * | 2010-11-12 | 2012-05-18 | Washington State University Research Foundation | Peptidomimetic inhibitors of psma |
| US9315524B2 (en) * | 2012-05-07 | 2016-04-19 | Kumar Ranjan Bhushan | Magnetic resonance imaging agents for calcification |
| WO2013173583A1 (en) * | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Psma inhibitors |
| SMT202300035T1 (it) | 2013-03-15 | 2023-05-12 | Cancer Targeted Tech Llc | Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi |
| EP2842578B1 (en) * | 2013-08-27 | 2018-06-27 | GILUPI GmbH | Diagnostic device for the detection of biomarkers |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| WO2015073678A1 (en) | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| KR101639599B1 (ko) * | 2015-11-09 | 2016-07-14 | 서울대학교산학협력단 | 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물 |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| MX392700B (es) * | 2016-08-10 | 2025-03-11 | Cancer Targeted Tech Llc | Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados. |
| MX2020010813A (es) | 2018-04-17 | 2021-01-08 | Endocyte Inc | Metodos de tratamiento de cancer. |
| WO2020030954A1 (en) | 2018-08-09 | 2020-02-13 | Integrative Medicine Clinic, Sia | Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer |
| JP7429688B2 (ja) * | 2018-09-21 | 2024-02-08 | エンドサイト・インコーポレイテッド | シールド剤およびそれらの使用 |
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| CN110305187B (zh) * | 2019-06-06 | 2021-02-23 | 原子高科股份有限公司 | 前列腺癌PET诊断试剂68Ga-NOTA-ANCP-PSMA及其制备方法和应用 |
| CN110305186B (zh) * | 2019-06-06 | 2021-02-23 | 原子高科股份有限公司 | 前列腺癌PET诊断试剂68Ga-DOTA-ANCP-PSMA及其制备方法和应用 |
| WO2021046233A1 (en) | 2019-09-03 | 2021-03-11 | Cancer Targeted Technology Llc | Chelate-containing psma inhibitors |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
| WO2024050440A2 (en) * | 2022-08-30 | 2024-03-07 | The Regents Of The University Of California | Prostate-specific membrane antigen targeted deep-tumor penetration of polymer nanodrugs and methods of use thereof |
| WO2025137443A1 (en) | 2023-12-22 | 2025-06-26 | Rayzebio, Inc. | Radiopharmaceutical compositions targeting somatostatin receptors and uses thereof |
| AR134788A1 (es) | 2023-12-22 | 2026-04-01 | Rayzebio Inc | Radiofármacos dirigidos al receptor 2 de somatostatina y sus usos |
| WO2026101949A1 (en) | 2024-11-06 | 2026-05-15 | Rayzebio, Inc. | Compounds targeting carbonic anhydrase ix and uses thereof |
| WO2026128542A1 (en) | 2024-12-11 | 2026-06-18 | Rayzebio, Inc. | Radiopharmaceutical compositions targeting glypican-3 and uses thereof |
| WO2026136824A1 (en) | 2024-12-20 | 2026-06-25 | Rayzebio, Inc. | Radiopharmaceutical compositions targeting alpha v beta 6 integrin receptor and method of uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1545498A4 (en) * | 2002-09-06 | 2006-09-06 | Us Gov Health & Human Serv | SCAFFOLD-SUBSTITUTED BIFUNCTIONAL DOTA LIGANDS, COMPLEXES AND COMPOSITIONS AND THEIR USE METHODS |
| PL1999136T3 (pl) * | 2006-03-14 | 2013-03-29 | Cancer Targeted Tech Llc | Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania |
| DK2187965T3 (da) * | 2007-08-17 | 2020-01-20 | Purdue Research Foundation | Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse |
| WO2012064914A2 (en) | 2010-11-12 | 2012-05-18 | Washington State University Research Foundation | Peptidomimetic inhibitors of psma |
-
2012
- 2012-06-13 PL PL12731239T patent/PL2721039T3/pl unknown
- 2012-06-13 WO PCT/US2012/042283 patent/WO2012174136A1/en not_active Ceased
- 2012-06-13 ES ES12731239.5T patent/ES2657863T3/es active Active
- 2012-06-13 US US14/126,296 patent/US9446157B2/en active Active
- 2012-06-13 EP EP12731239.5A patent/EP2721039B1/en active Active
- 2012-06-13 CN CN201280039876.6A patent/CN103930432B/zh active Active
- 2012-06-13 CA CA2839195A patent/CA2839195C/en active Active
- 2012-06-13 CN CN201710400001.9A patent/CN107325127B/zh active Active
-
2016
- 2016-08-24 US US15/246,483 patent/US9974869B2/en active Active
-
2018
- 2018-01-17 US US15/873,249 patent/US10166301B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012174136A1 (en) | 2012-12-20 |
| CN107325127A (zh) | 2017-11-07 |
| ES2657863T3 (es) | 2018-03-07 |
| CN103930432A (zh) | 2014-07-16 |
| CA2839195A1 (en) | 2012-12-20 |
| CN107325127B (zh) | 2020-09-01 |
| CN103930432B (zh) | 2017-06-23 |
| US20170072075A1 (en) | 2017-03-16 |
| US20180207298A1 (en) | 2018-07-26 |
| US20140241985A1 (en) | 2014-08-28 |
| US9974869B2 (en) | 2018-05-22 |
| EP2721039A1 (en) | 2014-04-23 |
| CA2839195C (en) | 2021-10-26 |
| US10166301B2 (en) | 2019-01-01 |
| US9446157B2 (en) | 2016-09-20 |
| EP2721039B1 (en) | 2018-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273079B (en) | Heterocycloamines as pi3k inhibitors | |
| PL2710007T3 (pl) | Inhibitory kinazy | |
| ZA201307016B (en) | Glucosylceramide synthase inhibitors | |
| ZA201404156B (en) | Kinase inhibitors | |
| EP2709486A4 (en) | TOOL WITH MULTIPLE APPLICATORS | |
| IL229028A0 (en) | Kinase inhibitors | |
| EP2782580A4 (en) | SELECTIVE INHIBITORS OF KINASES | |
| ZA201404157B (en) | Kinase inhibitors | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| ZA201306074B (en) | Cathepsin c inhibitors | |
| GB201120474D0 (en) | Inhibitors | |
| GB201104399D0 (en) | Novel inhibitors | |
| GB201115585D0 (en) | Base for construction | |
| GB201018597D0 (en) | Inhibitors | |
| SG10201602021WA (en) | Glucosylceramide synthase inhibitors | |
| AU339938S (en) | Slide |